Background: TNF-α has been proposed as a predictive factor for venous thromboembolism (VTE). Genetic polymorphisms could regulate TNF-α production. However, the relationship between TNFA gene variants and VTE is not clarified. This study aims to investigate the predictive role of five different TNFA gene promoter SNPs, or their haplotype combination(s), for a first VTE episode in gastrointestinal cancer out-patients treated with chemotherapy.
introduction Recent epidemiological and clinical data support the concept of an intensive cross-talk between the inflammatory network and procoagulant state of patients with cancer [1] . Among the proinflammatory gene products involved in such interactions, tumour necrosis factor-α (TNF-α) represents a key player [2, 3] . Earlier studies showed that TNF-α infusion was rapidly followed by thrombin generation [4, 5] , eventually associated to autoptic findings of deep vein thrombosis (DVT) [5] .
Subsequent studies confirmed an association between venous thromboembolism (VTE) and markers of inflammation [6] , TNF-α possibly representing a risk determinant for VTE, as individuals with detectable levels had a 2-fold increased risk in the Leiden Thrombophilia Study [7] . Recently, we demonstrated that elevated TNF-α levels increase VTE risk through impairment of the anticoagulant protein C system in metastatic colorectal cancer (mCRC) treated with chemotherapy [8] .
TNF-α production is regulated at many levels and can be controlled by genetic polymorphisms, especially in the promoter region [9] . In particular, TNFA -308G/A [10] and -857C/T [11, 12] single nucleotide polymorphisms (SNPs) were associated with increased cytokine production. Interestingly, both SNPs would represent a risk factor for CRC [13] or gastric cancer [14, 15] . Nonetheless, to the best of our knowledge, only rare studies focused on the association between TNFA SNPs and clinical outcome of gastrointestinal (GI) cancer patients [15] , and one study only investigated the possible association of TNFA -308G/A with VTE, rejecting the hypothesis of their relationship [16] . Based on the above reported observations, we decided to resume the original theory that TNFA SNPs might be involved in VTE risk and retrospectively evaluated whether five different TNFA gene promoter SNPs, or their haplotype combination(s), could be predictive of a first VTE in GI cancer out-patients in whom chemotherapy might act as thrombotic trigger.
patients and methods patients and sample collection A cohort of 157 Caucasian patients with histologically diagnosed GI cancer, treated at the Medical Oncology Unit of the 'Tor Vergata' Clinical Center, was enrolled. Patients were required to be at the start of a first chemotherapy regimen. Patient characteristics are summarized in Table 1 . Exclusion criteria were ECOG-PS>2, therapeutic doses of any heparin before enrolment or treatment with anticoagulant drugs, age <18 years or unwillingness to provide informed consent. No patient received prophylactic treatment with any anticoagulant drug after chemotherapy start. All patients were seen regularly at their scheduled chemotherapy visits or at the occurrence of clinically suspected VTE. DVT was confirmed by venography or colour-coded duplex sonography (in proximal DVT only). Pulmonary embolism (PE) was diagnosed by spiral computed tomography.
One hundred and fifty-seven sex-matched unrelated controls (68 ± 16 years) from the same geographical area of the patients were recruited from healthy individuals enrolled in the Interinstitutional Multidisciplinary Biobank (BioBIM) of the IRCCS San Raffaele, Rome, Italy.
Written informed consent was obtained from each participating subject, and the study was carried out under the appropriate institutional ethics approvals and in accordance with the principles embodied in the Declaration of Helsinki.
sample collection and TNF-α determination Blood samples were obtained by all subjects at time of enrolment, processed, aliquoted and stored at −80°C in the facilities of the BioBIM. Storage conditions were carefully maintained and aliquots were limited to one freeze-thaw cycle to ensure proper quality.
TNF-α levels were measured by enzyme-immunoassay (R&D Systems, MN) according to the manufacturers' instructions. All samples were assayed in duplicate and those showing values above the standard curve were re-tested with appropriate dilutions. All measurements were ascertained while blinded to the patient outcome. molecular analyses TNFA gene promoter polymorphisms DNA was isolated from EDTA anticoagulated whole blood using MagNA Pure LC instrument (Roche Diagnostics) and the MagNA Pure LC total DNA isolation kit I (Roche Diagnostics) according to the manufacturer's instructions.
TNFA (OMIM # 191160) -863C/A (rs 1800630) and -857C/T (rs 1799724) SNPs were determined by a 132-bp PCR amplification spanning from nucleotide (nt)-1117 to nt-985; -376G/A (rs1800750), -308G/A (rs1800629) and -238G/A (rs361525) gene promoter polymorphisms were determined by a 380-bp PCR amplification spanning from nt-667 to nt-287 based on the first translating nt of TNFA Ensembl sequence (Ensembl Transcript ID ENST00000229681).
Standard PCR was carried out using the primers: and an annealing temperature of 60°C for both reactions. Direct sequencing analyses were carried out to exclude pre-analytical and analytical errors on both strands using Big Dye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems), run on an ABI 3130 Genetic Analyzer (Applied Biosystems), and repeated on PCR products obtained from new nucleic acid extractions.
statistical analysis
Data are presented as percentages, mean ± SD, or median and interquartile ranges (IQR). Allelic frequencies were estimated by gene counting and genotypes were scored. Frequencies of each TNFA SNPs genotype were compared with those expected for a population in Hardy-Weinberg A total of 157 patients entered the study on the hypothesis that this number will detect a difference with a probability of 98%, at a two-sided 5% significance level, if the true hazard ratio (HR) is 2. This was based on the assumption of an accrual period of 2 years, an elapsed time between cycles within 30 days and a median TTE of 2.5 months. Only two-tailed probabilities were used for testing statistical significance. Only P-values lower than 0.05 were regarded as statistically significant. Calculations were made using a computer software package (Statistica 8.0, StatSoft, Inc., OK) or free web-based applications (http://statpages.org/).
results
The promoter region of the TNFA gene was screened for -863C/A, -857C/T, -376G/A, -308G/A and -238G/A SNPs using PCR amplification and direct sequencing analysis in 314 subjects, including 157 GI cancer patients and 157 unrelated controls. Genotypes and corresponding allele frequencies did not differ between patient and controls (supplementary Table S1 , available at Annals of Oncology online). Both groups were in Hardy-Weinberg equilibrium.
All patients were followed-up for a median period of 12 months, or until time of event. Data were collected by two independent oncologists. No patient underwent surgery during follow-up, nor was admitted to clinic for an acute medical illness requiring thromboprophylaxis. VTE occurred in 10% (4 PE and 11 DVT) of GI cancer patients (median TTE: 3 months), in agreement with previous reports [8, 18] . In particular, seven (three non-fatal sub-segmental PE and 4 DVT) patients were incidentally diagnosed with asymptomatic VTE at time of CT scan for restaging. The remaining eight patients had symptomatic VTE. No patient had an asymptomatic VTE on outset.
SNPs analysis of observed allele and genotype frequencies showed a significant association in a co-dominant inheritance model of the TNFA -857 T allele [odds ratio (OR) = 6.5; P = 0.003] in GI cancer patients who developed VTE during chemotherapy compared with those who did not (supplementary Table S2 , available at Annals of Oncology online). Furthermore, haplotype frequency estimation in the overall population of 314 subjects showed the presence of a fiveloci (-863C/-857 T/-376G/-308G/-238G) haplotype (CTGGG haplotype), which frequency was significantly higher in GI cancer patients who developed VTE compared with those who did not (OR = 2.7, P = 0.04) ( Table 2 ). GI patients who remained VTE free during chemotherapy did not differ in CTGGG haplotype frequency from controls ( Table 2 ). The prevalence of the other observed haplotypes was comparable between cases and controls. Linkage disequilibrium (LD) analysis, defined by the D 0 coefficient, revealed no LD between all five TNFA promoter SNPs.
Pre-chemotherapy serum TNF-α levels were higher in GI cancer patients compared with controls [5.0 (2.1-12.6) versus 1.1 (0.1-7.0) pg/ml, P < 0.0001], as previously shown [8] , and in metastatic compared with non-metastatic GI cancer (P = 0.046). Pre-chemotherapy serum TNF-α levels were higher in GI cancer patients who developed VTE during chemotherapy compared with those who did not [14.8 (3.4-52.5) versus 4.8 (1.9-10.1) pg/ml, P = 0.017], as previously reported [8] . Although, no association could be observed between serum TNF-α levels and TNFA genotypes or haplotypes (data not shown) both were independent predictors of VTE at multivariate analysis (regression coefficient for CTGGG haplotype = 0.754, P < 0.0001; regression coefficient for serum TNF-α levels = 0.337, P < 0.05).
Of interest, 11 (20%) of 56 GI cancer patients carrying CTGGG haplotype developed VTE compared with 4 (4%) of the remaining 101 patients (P = 0.003). Univariate Coxproportional hazards survival analysis showed that the presence of the CTGGG haplotype was able to significantly predict VTE with a HR of 5.6 [95% confidence interval (CI) 1.8-17.6; P = 0.003]. These values were substantially unmodified after adjustment for age, sex, site of primary, metastasis, ECOG-PS, concurrent treatment with bevacizumab and class of risk Table S3 , available at Annals of Oncology online). Kaplan-Meier curves for patients stratified on the basis of the presence of the CTGGG haplotype showed that patients who carried the haplotype had a worst 1-year VTE-free survival (79%) compared with patients who did not carry CTGGG haplotype (96%, Log-rank test = 3.43, P = 0.001) (Figure 1) .
discussion
These results demonstrate, for the first time to our knowledge, that TNFA gene promoter SNPs may predispose GI cancer patients to develop a first VTE episode during chemotherapy.
In particular, the TNFA -857 SNP was associated to VTE in a co-dominant inheritance model, with the T allele predisposing to VTE. Moreover, the presence of a five-loci CTGGG haplotype was associated to VTE both in haplotype association studies and in Cox proportional hazards analysis. Our results are in agreement with a former study demonstrating a lack of association between the TNFA -308G/A SNP and VTE [16] . Conversely, the findings here reported extend these previous observations suggesting that TNFA sequence variants different from -308 G/A SNP, either alone or as a specific haplotype combination, might be involved in VTE onset, at least under particular triggers, such as chemotherapy. Chemotherapy is associated with a 2-to 6-fold increased VTE risk, especially during the first 3 months [8, 18] , as the result of haemostatic activation, possibly related to an increased inflammatory status [8] . Indeed, experimental and clinical evidences support the capability of anti-cancer drugs to induce an adaptive stress response in the neoplastic environment [20] . TNF-α is a product of the acute phase response, and its production is regulated at many levels under stress conditions and is under control of genetic polymorphisms [9] . In particular, TNFA -308A allele [10] , -857 T allele and -863A allele [11, 12] have been associated with increased cytokine production. Thus, it was tempting to hypothesize that variations in TNF-α production (as a functional consequence of TNFA gene promoter polymorphisms) could be responsible for VTE onset under triggering conditions, i.e. chemotherapy. Accordingly, this study was designed as a case-control study in which the contribution of TNFA SNPs to the development of VTE was investigated in association to serum TNF-α levels. However, the increased frequency of the TNFA -857 T allele or the CTGGG haplotype in GI cancer patients who developed VTE did not associate with increased serum TNF-α levels. These results are in agreement with recent findings that could not confirm any functional relevance of any single TNFA SNPs, or the ancestral haplotype of the TNFA gene promoter -238G/-308G/-857 T, on transcriptional as well as post-translational levels, at least in healthy individuals [21] . Moreover, a metaanalysis conducted by the same authors confirmed the lack of association between TNF-α production and the TNFA SNPs analysed [21] .
Thus, it is logical to conclude that the increased VTE frequency found in carriers of the CTGGG haplotype may be due to mechanisms different from increased TNF-α production. Indeed, the TNFA SNPs could affect the production of other cytokines, as the gene lies with other inflammatory genes within the major histocompatibility complex, a genetic region characterised by strong linkage disequilibrium. Another explanation might come from the fact that TNF-α was measured before chemotherapy start and, due to the retrospective nature of the study, no serial measurements during treatment were carried out. Thus, we may not exclude the possibility that chemotherapy might have acted as a trigger for sustained production of TNF-α only in carriers of the TNFA -857 T allele or CTGGG haplotype during early cycles of chemotherapy, a timing that is consistent with data demonstrating an increase of TNF-α after the first two cycles of platinum-based chemotherapy [22] .
There are of course other limitations to acknowledge. First of all, the study was a retrospective analysis. However, all eligible consecutive patients within the designated timeframe were included, and all measurements were carried out while blinded to the patient outcome. Moreover, recruitment was carried out in a single Institution, which might have posed further limitation as the primary and most obvious shortcoming of single-centre studies is their potentially limited external validity. A final issue is represented by the relatively small sample size, ultimately leading to a small number of patients who actually developed VTE and large confidence intervals in the statistically significant findings. This might have affected the 'true' incidence of VTE or site-related rates, which, however, was not the purpose of our study.
In conclusion, the results here reported suggest that TNFA might represent a candidate gene contributing to VTE pathogenesis in GI cancer patients. To the best of our knowledge, this is the first evidence of an association between TNFA gene promoter SNPs and VTE. At present, we may hypothesize that chemotherapy elicits an adaptive response (with disruption of vascular homeostasis and/or cytokine upregulation) mostly in individuals who carry the TNFA -857 T allele, or the CTGGG haplotype. Specifically designed studies are required to validate this hypothesis. Nonetheless, our present study suggests an involvement of TNFA SNPs in the original articles Annals of Oncology pathophysiology of VTE and indicates that GI cancer patients at increased VTE risk might be genetically identified and offered enhanced prophylaxis. Further multicentre prospective and validation cohort studies involving larger numbers of patients are needed to fully establish not only the predictive value of TNFA SNPs analysis during chemotherapy, but also the economic impact of its routine use to identify at-risk cancer patients, which may benefit from thromboprophylaxis.
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